Skip to main content

The National Council is examining the cost effects of cannabis in medicine

GLP National Councillor Fabienne Stämpfli has submitted a motion instructing the Federal Council to examine whether a wider use of cannabis-based medicines could lead to savings in the healthcare system. Furthermore, the motion calls for an investigation into the impact of including cannabis-based medicines in the Federal Office of Public Health's list of specialties.

Potential for lower healthcare costs

Many patients report that they have been able to reduce or even completely discontinue other medications thanks to cannabis-based medicines. At the same time, many experience improvements in their quality of life, sleep quality, and, in some cases, their ability to work. However, these potential cost savings and economic benefits have so far received little systematic investigation.

Access is expensive

Although doctors have been allowed to prescribe cannabis-based medicines without special authorization since 2022, most patients have to pay for their treatment themselves. An estimated 10,000 people in Switzerland rely on cannabis-based medicines, while only around 70 receive reimbursement from their health insurance. Significant price differences between pharmacies further increase the financial burden for patients.

MEDCAN welcomes the examination

We expressly welcome this initiative. For years, those affected have reported that cannabis-based medicines not only alleviate symptoms but can also often reduce the need for other medications. A scientifically sound analysis of the actual costs and benefits is therefore long overdue.

This initiative is an important step towards an objective discussion about the role of cannabis in medicine and could help to improve access for patients in the long term.